Stand Up 2 Cancer

Watch "The Cure is Within" video and see how our teams are taking precision medicine to the next level, identifying specific gene mutations, developing customized treatments, and taking outcomes from "inoperable" to "incredible."

  • SLIDE1

    Watch "The Cure is Within" video and see how our teams are taking precision medicine to the next level, identifying specific gene mutations, developing customized treatments, and taking outcomes from "inoperable" to "incredible."

  • SLIDE2

    Penn's Abramson Cancer Center is proud to support Stand Up 2 Cancer in its mission to accelerate translational and innovative cancer research.

  • SLIDE3

    Penn's Director of Translational Research, Robert Vonderheide, MD, DPhil is co-leading the Lustgarten Foundation Pancreatic Cancer Convergence Dream Team.

  • SLIDE4

    At Penn, patients have access to the very latest research and clinical trials, assuring them the most advanced treatments possible.

  • SLIDE5

    The Abramson Cancer Center ranks 2nd in research funding from the National Institutes of Health (NIH), and is top 5 in National Cancer Institute (NCI) research funding nationally—a testament to the high quality of research that takes place at Penn Medicine.

Stand Up To Cancer: Fundraising that Benefits Cancer Research

Stand Up to Cancer (SU2C) brings together Dream Teams of the best and the brightest researchers across disciplines, institutions, countries and specialties to join in a unified fight against cancer with translational research.

Transforming Pancreatic Cancer to Treatable Disease

The newly announced SU2C-Lustgarten Foundation Pancreatic Cancer Convergence Dream Team is co-led by Penn Medicine's own director of Translational Research, Robert Vonderheide, MD, DPhil.

Calling on Penn Medicine's advances in the study of immunotherapy as an exciting new treatment option for leukemia and melanoma, this Dream Team hopes to apply a similar approach to treating pancreatic cancer.

Learn more about the Lustgarten Foundation Pancreatic Cancer Convergence Dream Team

Immunotherapy and Pancreatic Research Breakthroughs at Penn